U.S. markets closed

Nanobiotix S.A. (NBTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.66+0.01 (+0.15%)
At close: 11:15AM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Voting Rights and Shares Capital of the Company

    In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable

  • GlobeNewswire

    Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

    PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on


    Baillie Gifford Bolsters Stake in Nanobiotix SA

    Baillie Gifford (Trades, Portfolio), the renowned investment management firm, has recently increased its investment in Nanobiotix SA, a company at the forefront of nanotechnology in cancer treatment. This transaction was executed at a trade price of $5.81 per share, reflecting a 48.18% change in the firm's holdings and a 6.21% ownership in Nanobiotix SA. Despite the significant addition, the trade had a negligible impact on Baillie Gifford (Trades, Portfolio)'s portfolio, with the position accounting for just 0.02% of its total investments.